It's not the end of the line for the drug, which Biohaven picked up in 2018, after it was shelved by AstraZeneca despite reaching the phase 2 trial stage in Parkinson's disease and MSA.

(RTTNews) - Biohaven Ltd. (BHVN) and Merus N.V. (MRUS) announced a research collaboration and licensing agreement aimed at co-developing three innovative bispecific antibody drug conjugates (ADCs).

Biohaven Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates that target neurological and psychiatric diseases.